Enodia Therapeutics, a French biotech company, is advancing first-in-class treatment for cancer, inflammatory diseases, and viral infections by targeting the translocon, a key gateway for protein secretion in the cell.

Harnessing a cutting-edge AI-driven approach, we are developing selective small molecule inhibitors that block secretion and promote the degradation of pathological proteins at their source.